Pacific Biosciences of California, INC 8-K filings

PacBio reported preliminary Q1 2024 revenue that was below expectations, leading to a reduced 2024 revenue guidance and a plan to cut operating expenses by $50-$75 million.

PacBio's fourth quarter revenue surged 113% year-over-year, fueled by strong demand for its Revio sequencing systems.